Aim: Pemetrexed is a commonly used chemotherapeutic agent for lung adenocarcinoma patients. We investigated the impact of the genetic polymorphisms on the therapeutic efficacy of pemetrexed in lung adenocarcinoma patients.
Materials & Methods: We performed genotying of 51 polymorphisms of 13 genes in 243 lung adenocarcinoma patients treated with pemetrexed as a single agent for second or more line of therapy.
Results: Total 12 polymorphisms in six genes were showed statistical significances in univariate analysis. After a false-discovery rate correction, the associations between GGH rs16930092 (p = 0.034) and rs10464903 (p = 0.034), and progression-free survival (PFS) were still conserved. Two polymorphisms in ATIC and GGH genes were associated with therapeutic efficacy in multivariate analysis: ATIC rs12995526 for tumor response (p = 0.014) and for overall survival (p = 0.006), and GGH rs16930092 (p = 0.009) for PFS.
Conclusion: This study shows that polymorphisms on genes related to the metabolic pathway of pemetrexed, especially, ATIC and GGH genes, would have a therapeutic implication in pemetrexed-treated patients with lung adenocarcinoma. Original submitted 10 May 2013; Revision submitted 27 June 2014.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs.15.14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
β-Catenin mediated TAM phenotype promotes pancreatic cancer metastasis via the OSM/STAT3/LOXL2 axis.
Neoplasia
December 2024
Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its aggressive nature and dismal prognosis, largely attributed to its unique tumor microenvironment. However, the molecular mechanisms by which tumor-associated macrophages (TAMs) promote PDAC progression, particularly the role of β-catenin signaling in regulating TAM phenotype and function, remain incompletely understood. Initially, we performed comprehensive analyses of RNA-seq and single-cell RNA-seq (scRNA-seq) datasets to investigate OSM and LOXL2 expression patterns in PDAC.
View Article and Find Full Text PDFAssessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.
Int J Cancer
December 2024
Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Chest x-ray (CXR) is widely used for lung cancer screening in Japan. We evaluated the sensitivity and specificity of CXR in detecting early lung cancer and its histological types. We cross-referenced lung cancer municipality screening data with the regional cancer registry database.
View Article and Find Full Text PDFEstablishing patient-derived tumor organoids of bone metastasis from lung adenocarcinoma reveals the transcriptomic changes underlying denosumab treatment.
Clin Exp Metastasis
December 2024
Department of Musculoskeletal Oncology, Spine Tumor Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Patient-derived tumor organoids (PDTOs) models have been widely used to investigate the response of primary cancer tissues to anti-cancer agents. Nonetheless, only few case study tried to establish PDTOs and test treatment response based on bone metastasis (BoM) tissues. Fresh BoM tissues were obtained from lung cancer (LC) patients who underwent spinal metastatic tumor surgery for PDTOs culture.
View Article and Find Full Text PDFRadiomics for differentiating adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer beyond nodule morphology in chest CT.
Sci Rep
December 2024
Department of Radiology and Imaging Sciences, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600 116, India.
Distinguishing between primary adenocarcinoma (AC) and squamous cell carcinoma (SCC) within non-small cell lung cancer (NSCLC) tumours holds significant management implications. We assessed the performance of radiomics-based models in distinguishing primary there is from SCC presenting as lung nodules on Computed Tomography (CT) scans. We studied individuals with histopathologically proven adenocarcinoma or SCC type NSCLC tumours, detected as lung nodules on Chest CT.
View Article and Find Full Text PDFHypoxia drives the formation of lung micropapillary adenocarcinoma-like structure through hypoxia-inducible factor-1α.
Sci Rep
December 2024
Department of Pathology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Micropapillary adenocarcinoma (MPC) is an aggressive histological subtype of lung adenocarcinoma (LUAD). MPC is composed of small clusters of cancer cells exhibiting inverted polarity. However, the mechanism underlying its formation is poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!